Literature DB >> 19721448

Comparison of indices of insulin resistance with metabolic syndrome classifications to predict the development of impaired fasting glucose in overweight and obese subjects: a 3-year prospective study.

B I Shand1, R S Scott, J G Lewis, P A Elder, C M Frampton.   

Abstract

OBJECTIVE: To compare the ability of biochemical indices of insulin resistance (IR) with metabolic syndrome (MetS) classifications to predict changes in blood glucose control over a 3-year period in overweight and obese subjects.
DESIGN: This was a longitudinal, prospective study, with data collected at baseline, 18 and 36 months. SUBJECTS AND METHODS: A total of 175 overweight (body mass index (BMI)>25 kg m(-2)) and obese (BMI>30 kg m(-2)) subjects were enrolled in the study. The IR indices assessed included fasting insulin concentration, the insulin/glucose-derived indices, homeostasis assessment model of insulin resistance (HOMA-IR) and quantitative insulin sensitivity check index (QUICKI), the insulin/triglyceride-derived McAuley index, plasma adiponectin concentration and the triglyceride (trig) and high-density lipoprotein (HDL)-cholesterol ratio (trig:HDL). The two MetS classifications were assessed according to the definitions of the National Cholesterol Education Program-Third Adult Treatment Panel (NCEP-ATPIII) and the International Diabetes Federation (IDF). The potential of the IR indices and MetS classifications at baseline to predict the development of impaired fasting glucose (IFG) was examined using receiver-operator characteristic (ROC) curve analysis and analysis of variance.
RESULTS: Complete data were collected on 158 subjects. In all, 51 (32%) subjects developed IFG during the study. The analysis of variance showed significant differences between the IFG and normoglycaemic group in the baseline values of the McAuley index, trig:HDL, plasma adiponectin concentration and prevalence of the MetS. The ROC curve analysis confirmed this result and showed that the strongest predictors of IFG were baseline trig:HDL and IDF MetS classification, followed in order by the McAuley index, plasma adiponectin concentration and NCEP-ATPIII MetS classification. In contrast, the baseline values of fasting insulin, HOMA-IR and QUICKI did not predict IFG. DISCUSSION: This study showed that the IR indices, derived, in part, from plasma triglyceride concentration, were sensitive predictors for the development of IFG in normoglycaemic overweight and obese subjects. Indices derived from glucose and insulin did not identify this at-risk group. The study also showed that the presence of MetS and its abnormalities of an increased trig:HDL ratio and low plasma adiponectin concentration were all sensitive predictors of IFG.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19721448     DOI: 10.1038/ijo.2009.169

Source DB:  PubMed          Journal:  Int J Obes (Lond)        ISSN: 0307-0565            Impact factor:   5.095


  3 in total

1.  Differential Association of Selected Adipocytokines, Adiponectin, Leptin, Resistin, Visfatin and Chemerin, with the Pathogenesis and Progression of Type 2 Diabetes Mellitus (T2DM) in the Asir Region of Saudi Arabia: A Case Control Study.

Authors:  Mohammad Muzaffar Mir; Rashid Mir; Mushabab Ayed Abdullah Alghamdi; Javed Iqbal Wani; Zia Ul Sabah; Mohammed Jeelani; Vijaya Marakala; Shahzada Khalid Sohail; Mohamed O'haj; Muffarah Hamid Alharthi; Mohannad Mohammad S Alamri
Journal:  J Pers Med       Date:  2022-05-01

2.  Adiponectin is Associated with Impaired Fasting Glucose in the Non-Diabetic Population.

Authors:  Sang Yeun Kim; Sun Ju Lee; Hyoun Kyoung Park; Ji Eun Yun; Myoungsook Lee; Jidong Sung; Sun Ha Jee
Journal:  Epidemiol Health       Date:  2011-08-20

3.  The association of adiponectin with risk of pre-diabetes and diabetes in different subgroups: cluster analysis of a general population in south China.

Authors:  Xun Gong; Lili You; Feng Li; Qingyu Chen; Chaogang Chen; Xiaoyun Zhang; Xiuwei Zhang; Wenting Xuan; Kan Sun; Guojuan Lao; Chuan Wang; Yan Li; Mingtong Xu; Meng Ren; Li Yan
Journal:  Endocr Connect       Date:  2021-11-03       Impact factor: 3.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.